Back

Decentralized donor-derived cell-free DNA testing for cardiac allograft rejection: clinical validation and additive value beyond standard-of-care monitoring

10 May 2026 (09:56 - 10:07)
Organised by: Logo
Congress Presentation Part of: Advanced heart failure therapies: devices, transplantation, and mechanical support Heart Transplantation Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maria Francesca Scuppa

Alma Mater Studiorum, University of Bologna, Bologna (Italy)

3 More presentations in this session

Presentation thumbnail
Ultra-long-term outcomes after lvad support in older adults: insights from the STELLAR registry
Doctor C. Velasquez-Silva (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
Impact of cancer history on outcomes after HeartMate 3 left ventricular assist device implantation in the momentum 3 studies
Doctor J. Raikhelkar (New York, US)
Abstract Slides Video
Presentation thumbnail
Individualized treatment responses to cardiac resynchronization therapy: a cluster analysis of the Swedish heart failure registry
Doctor R. Laborante (Stockholm, SE)
Abstract Video

Access the full session

Session thumbnail
Advanced heart failure therapies: devices, transplantation, and mechanical support
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 09:56 CET
You may be interested in
thumbnail
Congress Presentation
Role of NTproBNP and donor-derived cell-free DNA in the diagnosis of acute rejection in heart transplant recipients: a prospective study
thumbnail
Congress Presentation
Improvements in post-HTx care for better long-term outcomes
thumbnail
Congress Presentation
Donor-derived cell-free DNA first validated for noninvasive monitoring of acute rejection in an asian heart transplant population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources